Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma

Cancer

Volumn 83, Issue 10, 1998, Pages 2194-2200

  Berruti, Alfredo ^a   Terzolo, Massimo ^a   Pia, Anna ^a   Angeli, Alberto ^a   Dogliotti, Luigi ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Adrenocortical carcinoma; Cisplatin; Doxorubicin; Etoposide; Mitotane

Indexed keywords

CHOLESTEROL; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOTANE; TRIACYLGLYCEROL;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PATIENT CODING; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; MITOTANE; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032533913     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3     Document Type: Article

References (32)

1. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian registry for adrenal cortical carcinoma: analysis of a multi-institutional series of 129 patients. Surgery 1996;119:161-70.
2. Dogliotti L, Berruti A, Pia A, Paccotti P, Alì A, Angeli A. Cytotoxic chemotherapy for adrenocortical carcinoma. Minerva Endocrinol 1995;20:105-9.
3. Luton JP, Cerdas S, Billaud L, Thomas G, Guillhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.
4. Bodie B, Novick AC, Pontes E, Straffon RA, Montie JE, Babiak T, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141:257-60.
5. Wooten MD, King DK. Adrenal cortical carcinoma: epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55.
6. Haak HR, Hermans J, van de Velde CJH, Lentjes EGWM, Goslings BM, Fleuren GH, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-51.
7. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, et al. Eastern Cooperative Oncology Group Study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;11:1006-13.
8. Tattersall MH, Lander H, Bain B, Stocks AE, Woods RL, Fox RM. Cisplatinum treatment of metastatic adrenal carcinoma. Med J Aust 1980;1:419-21.
9. Chun HG, Yagoda A, Kemeny N. Cisplatinum for adrenal cortical cancer. Cancer Treat Rep 1983;67:513-4.
10. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 1991;67:2997-3000.
11. van Slooten H, van Oosterom. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67:377-9.
12. Hesketh PJ, McCaffey RP, Finkel HF, Larmon SS, Griffing GT, Melby JC. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1986;71:222-4.
13. Burgess MA, Legha SS, Sellin RV. Chemotherapy with cisplatinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma (ACC) [abstract]. Proc Am Soc Clin Oncol 1993;12:188.
14. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992;112:981-6.
15. Bates SE, Shieh CY, Mickley LA, Dicheck HL, Gazdar A, Loriaux DL, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73:18-29.
16. Bukowsky RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993;11:161-5.
17. Teicher BA. Lonidamine: in vitro/in vivo correlations. Eur J Cancer 1994;30A:1411-3.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 1982;5:649-55.
19. WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization, 1979.
20. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke B, et al. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
21. Berruti A, Terzolo M, Paccotti P, Veglio F, Pia A, Dogliotti L, et al. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Tumori 1992;78:345-8.
22. Pia A, Berruti A, Terzolo M, Paccotti P, Letizia C, Dogliotti L, et al. Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients: report on 7 cases. Ann Oncol 1995;6:509-10.
23. Roila F and the Italian Group for Antiemetic Research. Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Oncology 1996;53(Suppl 1):65-72.
24. Lanser JBK, van Seters AP, Moolenar AJ, Haak HR, Bollen EL. O,p′-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol 1982;5:70-6.
25. van Slooten H, van Seters AP, Smeenk D, Moolenar AJ. Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms. J Clin Oncol 1992;10:1504.
26. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:57-63.
27. Vassilopoulu Sellin R, Saaman NA. Mitotane administration: an unusual cause of hypercholesterolemia. Horm Metab Res 1991;23:619-20.
28. Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p′-DDD-induced hypercholesterolemia. Q J Med 1992;84:671-9.
29. Gebhardt DOE, Moolenar AJ, van Seters AP, van der Velde EA, Gevers Leuven JA. The distribution of o,p′-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemother Pharmacol 1992;29:331-4.
30. Freeman DA. Steroid hormone-producing tumors in man. Endocr Rev 1986;7:204-20.
31. van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 1991;124:526-33.
32. Robinson BG, Hales IB, Henniker Ho K, Luttrell BM, Smee IR, Stiel JN. The effects of o,p′-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol 1987;27:437-44.